Isifundo Esisha Siqondise Okumaphakathi kuya Kunzima Kwamathambo Edolo

I-Ageless Biotech, Inc. U-Sheridan, WY inkampani ye-biotech eyakhelwe ukuletha ukwelapha okusekelwe ku-stem cell emakethe, ithole i-US Food and Drug Administration (FDA) Investigational New Drug Application (IND) yokwelapha i-Osteoarthritis of the Knee.              

I-Arthritis Foundation ichaze i-Osteoarthritis “njengesifo esingelapheki … esingelapheki.” Eminyakeni eyishumi edlule ngo-2009 i-ABC News yanyatheliswa, ukunakekelwa kwezokwelapha kweziguli ze-osteoarthritis e-United States kubiza u-$ 185.5 billion ngonyaka.

Eminyakeni emi-4 nje emifushane, kusukela ku-2009 Arthritis Foundation kubika izindleko ze-OA e-USA ziphindwe kabili njengoba zishicilelwe ngo-2013 umbiko we-CDC wokuthi izindleko zonyaka ze-Osteoarthritis "zazingu-$ 303.5 billion noma i-1% ye-2013 US Gross Domestic Product (GDP) .”  

Umongameli we-Ageless Biotech, Inc, u-Vince Liguori uveza, “ukutholwa kwe-Stage II OA ye-Knee Clinical Trial kusivumela ukuthi siqale izivivinyo ngokushesha okukhulu ngezinhlelo ezizoqala ekupheleni kuka-March 2022. Le FDA Accepted IND ivumela i-Ageless I-Biotech ukuletha umkhiqizo we-Osteoarthritis Stem Cell kubo bobabili Odokotela Neziguli ngokushesha. ”

I-Ageless Biotech IND isebenzisa amaseli e-Adipose Derived Stem Cell asetshenziswe kancane ngaphandle kwama-enzyme noma amanye amakhemikhali ngenqubo yobunikazi yendlela eyaziwa kakhulu ngokuthi i-Stromal Vascular Fraction (SVF) edala i-matrix yamaseli omuntu aphilayo. I-Ageless Biotech ihlela ukufakazela izici ezivuselelayo zoMkhiqizo we-Ageless Biotech SVF ngaphambi kokuphela kwalolu cwaningo olwamukelekile lwe-FDA ngenkathi ngesikhathi esifanayo lubonisa ukuphepha kanye nesikhathi esincane sokuphumula sesiguli. I-Ageless Biotech ikholelwa ukuthi izigidi zokuhlinzwa kwamadolo kwaminyaka yonke zizothathelwa indawo ngomjovo owodwa olula wamadolo. Nakuba sikholelwa ukuthi lobu buchwepheshe buzogcina bunikezwe ilayisense kodokotela ukuze lusatshalaliswe ngobuningi, sihlola ngokujulile izinketho zokuthobela Uhlobo lwe-HLA ukuze sincome lezi zindlela zokwelapha esikhathini esizayo "okungekude".

Umqondisi Wezokuthengisa Kazwelonke we-BioXstem, kanye neLungu Lebhodi Le-Ageless Biotech u-Jon Youngs ukubeka kahle kakhulu ngokuthi, “Thina kwa-BioXstem sijabule kakhulu ukuba abatshalizimali abakhuthele be-Ageless Biotech kangangokuthi manje asisakhulumi ngakho nje. Singasho ukuthi sibamba iqhaza ngenkuthalo ku-FDA IND kanye nengxenye yomuthi othuthukisa ubuholi. "